carbamates has been researched along with Hepatic Encephalopathy in 5 studies
Hepatic Encephalopathy: A syndrome characterized by central nervous system dysfunction in association with LIVER FAILURE, including portal-systemic shunts. Clinical features include lethargy and CONFUSION (frequently progressing to COMA); ASTERIXIS; NYSTAGMUS, PATHOLOGIC; brisk oculovestibular reflexes; decorticate and decerebrate posturing; MUSCLE SPASTICITY; and bilateral extensor plantar reflexes (see REFLEX, BABINSKI). ELECTROENCEPHALOGRAPHY may demonstrate triphasic waves. (From Adams et al., Principles of Neurology, 6th ed, pp1117-20; Plum & Posner, Diagnosis of Stupor and Coma, 3rd ed, p222-5)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The Daclatasvir and Sofosbuvir combination therapy (SOF/DCV) has shown efficacy in patients with chronic hepatitis C in clinical trials." | 9.27 | Sofosbuvir plus daclatasvir with or without ribavirin in 551 patients with hepatitis C-related cirrhosis, genotype 4. ( El-Amin, H; El-Khayat, H; Fouad, Y; Kamal, EM; Maher, M; Mohamed, HI; Risk, A, 2018) |
| "Sofosbuvir/velpatasvir (SOF/VEL) is expected to be highly effective, even in patients with decompensated liver cirrhosis." | 7.96 | Hepatitis C virus-associated decompensated liver cirrhosis with refractory hepatic encephalopathy successfully treated by balloon-occluded retrograde transvenous obliteration after sofosbuvir/velpatasvir. ( Kakizaki, S; Kizawa, K; Kosone, T; Marubashi, K; Sato, K; Shimizu, M; Takagi, H; Takakusagi, S; Uraoka, T; Yokoyama, Y, 2020) |
| "The Daclatasvir and Sofosbuvir combination therapy (SOF/DCV) has shown efficacy in patients with chronic hepatitis C in clinical trials." | 5.27 | Sofosbuvir plus daclatasvir with or without ribavirin in 551 patients with hepatitis C-related cirrhosis, genotype 4. ( El-Amin, H; El-Khayat, H; Fouad, Y; Kamal, EM; Maher, M; Mohamed, HI; Risk, A, 2018) |
| "Sofosbuvir/velpatasvir (SOF/VEL) is expected to be highly effective, even in patients with decompensated liver cirrhosis." | 3.96 | Hepatitis C virus-associated decompensated liver cirrhosis with refractory hepatic encephalopathy successfully treated by balloon-occluded retrograde transvenous obliteration after sofosbuvir/velpatasvir. ( Kakizaki, S; Kizawa, K; Kosone, T; Marubashi, K; Sato, K; Shimizu, M; Takagi, H; Takakusagi, S; Uraoka, T; Yokoyama, Y, 2020) |
| "Ascites and hepatic encephalopathy occurred in 10." | 1.48 | High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma. ( Aghemo, A; Aglitti, A; Andreone, P; Boccaccio, V; Bollani, S; Brunetto, MR; Bruno, S; Calvaruso, V; Ciancio, A; Coco, B; Conti, F; Degasperi, E; Di Leo, A; Di Marco, V; Giorgini, A; Lampertico, P; Lleo, A; Maisonneuve, P; Marzi, L; Persico, M; Rendina, M; Troshina, G; Villa, E; Zuin, M, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Takakusagi, S | 1 |
| Shimizu, M | 1 |
| Yokoyama, Y | 1 |
| Kizawa, K | 1 |
| Marubashi, K | 1 |
| Kosone, T | 1 |
| Sato, K | 1 |
| Kakizaki, S | 1 |
| Takagi, H | 1 |
| Uraoka, T | 1 |
| El-Khayat, H | 1 |
| Fouad, Y | 1 |
| Mohamed, HI | 1 |
| El-Amin, H | 1 |
| Kamal, EM | 1 |
| Maher, M | 1 |
| Risk, A | 1 |
| Persico, M | 1 |
| Aglitti, A | 1 |
| Aghemo, A | 1 |
| Rendina, M | 1 |
| Lleo, A | 1 |
| Ciancio, A | 1 |
| Di Marco, V | 1 |
| Lampertico, P | 1 |
| Brunetto, MR | 1 |
| Zuin, M | 1 |
| Andreone, P | 1 |
| Villa, E | 1 |
| Troshina, G | 1 |
| Calvaruso, V | 1 |
| Degasperi, E | 1 |
| Coco, B | 1 |
| Giorgini, A | 1 |
| Conti, F | 1 |
| Di Leo, A | 1 |
| Marzi, L | 1 |
| Boccaccio, V | 1 |
| Bollani, S | 1 |
| Maisonneuve, P | 1 |
| Bruno, S | 1 |
| Hanafy, AS | 1 |
| Bassiony, MA | 1 |
| Basha, MAA | 1 |
| Schneider, F | 1 |
| Lutun, P | 1 |
| Boudjema, K | 1 |
| Wolf, P | 1 |
| Tempé, JD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Real Life Experience in the Management of HCV Related Decompensated Cirrhosis With Direct Antiviral Agents[NCT03547895] | 80 participants (Actual) | Interventional | 2015-06-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for carbamates and Hepatic Encephalopathy
| Article | Year |
|---|---|
Sofosbuvir plus daclatasvir with or without ribavirin in 551 patients with hepatitis C-related cirrhosis, genotype 4.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; | 2018 |
4 other studies available for carbamates and Hepatic Encephalopathy
| Article | Year |
|---|---|
Hepatitis C virus-associated decompensated liver cirrhosis with refractory hepatic encephalopathy successfully treated by balloon-occluded retrograde transvenous obliteration after sofosbuvir/velpatasvir.
Topics: Balloon Occlusion; Carbamates; Female; Hepacivirus; Hepatic Encephalopathy; Hepatitis C; Heterocycli | 2020 |
High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma.
Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Cohort Studies; Drug | 2018 |
Management of HCV-related decompensated cirrhosis with direct-acting antiviral agents: who should be treated?
Topics: Adult; Antiviral Agents; Ascites; Carbamates; Drug Therapy, Combination; Esophageal and Gastric Vari | 2019 |
In vivo evidence of enhanced guanylyl cyclase activation during the hyperdynamic circulation of acute liver failure.
Topics: Adolescent; Adult; Atrial Natriuretic Factor; Blood Circulation; Carbamates; Cyclic GMP; Female; Gua | 1994 |